A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.
The FDA has approved incobotulinumtoxinA (Xeomin--Merz) for treatment of cervical dystonia and blepharospasm in adults. It has been commercially available in Germany since 2005. Several formulations of botulinum toxin type A (Botox; Dysport) and type B (Myobloc) are already marketed for treatment of cervical dystonia. Botox is also approved for treatment of blepharospasm.
D000818:Animals; D001764:Blepharospasm / Q000188:drug therapy* / Q000503:physiopathology; D001905:Botulinum Toxins / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D002626:Chemistry, Pharmaceutical; D006801:Humans; D018908:Muscle Weakness / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D014103:Torticollis / Q000188:drug therapy* / Q000503:physiopathology
D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA